Your browser doesn't support javascript.
Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.
Shtro, Anna A; Petukhova, Galina D; Romanova, Aleksandra S.
  • Shtro AA; Smorodintsev Research Institute of Influenza, Professora Popova Str. 15/17, 197376 Saint Peterburg, Russia.
  • Petukhova GD; Smorodintsev Research Institute of Influenza, Professora Popova Str. 15/17, 197376 Saint Peterburg, Russia.
  • Romanova AS; Smorodintsev Research Institute of Influenza, Professora Popova Str. 15/17, 197376 Saint Peterburg, Russia.
Molecules ; 27(7)2022 Mar 31.
Article in English | MEDLINE | ID: covidwho-1785839
ABSTRACT
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI ribavirin (approved in a limited number of countries due to side effects) and palivizumab (Synagis), which is intended only for the prevention, but not the treatment, of infection. Currently, various research groups are searching for new drugs against RSV, with three main areas of research small molecules, polymeric drugs (proteins and peptides), and plant extracts. This review is devoted to currently developed protein and peptide anti-RSV drugs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Tract Infections / Respiratory Syncytial Virus Infections Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Infant Language: English Journal subject: Biology Year: 2022 Document Type: Article Affiliation country: Molecules27072263

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Tract Infections / Respiratory Syncytial Virus Infections Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Infant Language: English Journal subject: Biology Year: 2022 Document Type: Article Affiliation country: Molecules27072263